Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder

被引:18
作者
Lohoff, Falk W. [1 ]
机构
[1] Natl Inst Alcohol Abuse & Alcoholism, Sect Clin Genom & Expt Therapeut, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
alcohol; addiction; treatment; Personalized and Precision Medicine (PPM); mood disorder; NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; MENTAL-HEALTH; GLOBAL BURDEN; UNITED-STATES; DEPENDENCE; NALTREXONE; SERTRALINE; DRINKING; PHARMACOTHERAPY;
D O I
10.3389/fpsyt.2022.767506
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Alcohol Use Disorder (AUD) is a chronic psychiatric disorder marked by impaired control over drinking behavior that poses a significant challenge to the individual, their community, the healthcare system and economy. While the negative consequences of chronic excessive alcohol consumption are well-documented, effective treatment for AUD and alcohol-associated diseases remains challenging. Cognitive and behavioral treatment, with or without pharmaceutical interventions, remain the most commonly used methods; however, their efficacy is limited. The development of new treatment protocols for AUD is challenged by difficulty in accurately measuring patterns of alcohol consumption in AUD patients, a lack of a clear understanding of the neuropsychological basis of the disorder, the high likelihood of AUD patients relapsing after receiving treatment, and the numerous end-organ comorbidities associated with excessive alcohol use. Identification and prediction of patients who may respond well to a certain treatment mechanism as well as clinical measurement of a patient's alcohol exposure are bottlenecks in AUD research which should be further addressed. In addition, greater focus must be placed on the development of novel strategies of drug design aimed at targeting the integrated neural pathways implicated in AUD pathogenesis, so that next-generation AUD treatment protocols can address the broad and systemic effects of AUD and its comorbid conditions.
引用
收藏
页数:9
相关论文
共 88 条
[11]   Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders? [J].
Byrne, Simon P. ;
Haber, Paul ;
Baillie, Andrew ;
Giannopolous, Vickie ;
Morley, Kirsten .
SUBSTANCE USE & MISUSE, 2019, 54 (12) :2053-2063
[12]   The Clinical Efficacy of Mindfulness-Based Treatments for Alcohol and Drugs Use Disorders: A Meta-Analytic Review of Randomized and Nonrandomized Controlled Trials [J].
Cavicchioli, Marco ;
Movalli, Mariagrazia ;
Maffei, Cesare .
EUROPEAN ADDICTION RESEARCH, 2018, 24 (03) :137-162
[13]  
Centre N.I.,, 2009, STAT ALC ENGL
[14]   Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents [J].
Cornelius, Jack R. ;
Douaihy, Antoine ;
Bukstein, Oscar G. ;
Daley, Dennis C. ;
Wood, Scott D. ;
Kelly, Thomas M. ;
Salloum, Ihsan M. .
ADDICTIVE BEHAVIORS, 2011, 36 (08) :843-848
[15]   Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points [J].
Creswell, Kasey G. ;
Chung, Tammy .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 (10) :1874-1879
[16]   The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [J].
Degenhardt, Louisa ;
Charlson, Fiona ;
Ferrari, Alize ;
Santomauro, Damian ;
Erskine, Holly ;
Mantilla-Herrara, Ana ;
Whiteford, Harvey ;
Leung, Janni ;
Naghavi, Mohsen ;
Griswold, Max ;
Rehm, Juergen ;
Hall, Wayne ;
Sartorius, Benn ;
Scott, James ;
Vollset, Stein Emil ;
Knudsen, Ann Kristin ;
Haro, Josep Maria ;
Patton, George ;
Kopec, Jacek ;
Malta, Deborah Carvalho ;
Topor-Madry, Roman ;
McGrath, John ;
Haagsma, Juanita ;
Allebeck, Peter ;
Phillips, Michael ;
Salomon, Joshua ;
Hay, Simon ;
Foreman, Kyle ;
Lim, Stephen ;
Mokdad, Ali ;
Smith, Mari ;
Gakidou, Emmanuela ;
Murray, Christopher ;
Vos, Theo .
LANCET PSYCHIATRY, 2018, 5 (12) :987-1012
[17]   The Declining Efficacy of Naltrexone Pharmacotherapy for Alcohol Use Disorders Over Time: A Multivariate Meta-Analysis [J].
Del Re, A. C. ;
Maisel, Natalya ;
Blodgett, Janet ;
Finney, John .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (06) :1064-1068
[18]   Comparisons of alcohol consumption by timeline follow back vs. smartphone-based daily interviews [J].
Dulin, Patrick L. ;
Alvarado, Corene E. ;
Fitterling, James M. ;
Gonzalez, Vivian M. .
ADDICTION RESEARCH & THEORY, 2017, 25 (03) :195-200
[19]   The Neurobiological Mechanism of Chemical Aversion (Emetic) Therapy for Alcohol Use Disorder: An fMRI Study [J].
Elkins, Ralph L. ;
Richards, Todd L. ;
Nielsen, Robert ;
Repass, Richard ;
Stahlbrandt, Henriettae ;
Hoffman, Hunter G. .
FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2017, 11
[20]   The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids [J].
Forrest, E. H. ;
Morris, A. J. ;
Stewart, S. ;
Phillips, M. ;
Oo, Y. H. ;
Fisher, N. C. ;
Haydon, G. ;
O'Grady, J. ;
Day, C. P. .
GUT, 2007, 56 (12) :1743-1746